Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119

Article  PubMed  Google Scholar 

Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ et al (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378(9785):31–40

Article  CAS  PubMed  Google Scholar 

Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12):2032–2045

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basu S, Yudkin JS, Kehlenbrink S, Davies JI, Wild SH, Lipska KJ et al (2019) Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. Lancet Diabetes Endocrinol 7(1):25–33

Article  PubMed  Google Scholar 

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2019) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134(10):752–772

Article  Google Scholar 

Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255–270

Article  CAS  PubMed  Google Scholar 

Fonseca-Correa JI, Correa-Rotter R (2021) Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne) 8:777861

Article  PubMed  Google Scholar 

American Diabetes Association (2019) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 42(Suppl 1):S90-S102

Chao EC, Henry RR (2010) SGLT2 inhibition–a novel strategy for diabetes treatment. Nat Rev Drug Discov 9(7):551–559

Article  CAS  PubMed  Google Scholar 

Salah HM, Al’Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL et al (2021) Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J 232:10–22

Article  CAS  PubMed  Google Scholar 

Madaan T, Akhtar M, Najmi AK (2016) Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci 93:244–252

Article  CAS  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928

Article  PubMed  PubMed Central  Google Scholar 

Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I (2006) The case of the misleading funnel plot. BMJ 333(7568):597–600

Article  PubMed  PubMed Central  Google Scholar 

Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20(4):641–654

Article  CAS  PubMed  Google Scholar 

Wilding JP, Norwood P, T’Joen C, Bastien A, List JF, Fiedorek FT (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32(9):1656–1662

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S (2014) Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 16(2):124–136

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ et al (2014) Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37(7):1815–1823

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ (2015) Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 17(10):936–948

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K et al (2015) Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 38(3):403–411

Article  CAS  PubMed  Google Scholar 

Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2015) Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38(7):1218–1227

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishihara H, Yamaguchi S, Nakao I, Okitsu A, Asahina S (2016) Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab 18(12):1207–1216

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki K, Mitsuma Y, Sato T, Anraku T, Hatta M (2016) Comparison of combined tofogliflozin and glargine, tofogliflozin added to insulin, and insulin dose-increase therapy in uncontrolled type 2 diabetes. J Clin Med Res 8(11):805–814

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inagaki N, Harashima S, Maruyama N, Kawaguchi Y, Goda M, Iijima H (2016) Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol 15:89

Article  PubMed  PubMed Central  Google Scholar 

Araki E, Onishi Y, Asano M, Kim H, Yajima T (2017) Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes Obes Metab 19(4):562–570

Article  CAS  PubMed  Google Scholar 

Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K (2017) Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial. Diabetes Obes Metab 19(10):1397–1407

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seino Y, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, Sakai S (2018) Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period. Curr Med Res Opin 34(6):981–994

Article  CAS  PubMed  Google Scholar 

Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim JH et al (2018) Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: a randomized controlled trial. J Diabetes 10(7):589–599

Article  PubMed  Google Scholar 

Sone H, Kaneko T, Shiki K, Tachibana Y, Pfarr E, Lee J et al (2020) Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 22(3):417–426

Article  CAS  PubMed  Google Scholar 

Cheng R, Taleb N, Stainforth-Dubois M, Rabasa-Lhoret R (2021) The promising future of insulin therapy in diabetes mellitus. Am J Physiol Endocrinol Metab 320(5):E886-e890

Article  CAS  PubMed  Google Scholar 

Steenkamp D, Eby EL, Gulati N, Liao B (2022) Adherence and persistence to insulin therapy in people with diabetes: impact of connected insulin pen delivery ecosystem. J Diabetes Sci Technol 16(4):995–1002

Article  PubMed  Google Scholar 

Lee YB, Han K, Kim B, Choi MS, Park J, Kim M et al (2021) Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: a nationwide study. J Diabetes Investig 12(10):1855–1863

Article  PubMed  PubMed Central  Google Scholar 

Nordklint AK, Almdal TP, Vestergaard P, Lundby-Christensen L, Boesgaard TW, Breum L et al (2021) Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. Osteoporos Int 32(9):1837–1848

Article  CAS  PubMed  Google Scholar 

Gubitosi-Klug RA (2014) The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care 37(1):44–49

Article  PubMed  Google Scholar 

Min SH, Yoon JH, Hahn S, Cho YM (2017) Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev. https://doi.org/10.1002/dmrr.2818

Article  PubMed  Google Scholar 

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13(10):928–938

Article  CAS  PubMed